The filoviruses, the Ebola and Marburg viruses (EBOVs and MARVs), are NIAID category A priority pathogens which cause highly lethal hemorrhagic fever in humans with fatality rates approaching 90 percent. Identification of therapeutic targets and advancing medical countermeasures for these threats is of high priority. Despite this need, no approved therapeutics are available for filoviral infections. To address this unmet need we propose to develop small molecule therapeutics that specifically target viral innate immune evasion functions and viral transcription. The combination of approaches is expected to yield individual panfilovirus inhibitors with different mechanisms of action, which when combined are expected to act synergistically. Combining inhibitors of viral innate immune evasion with viral transcription inhibitors is particularly appealing, from the point of view of synergy. This is because specific suppression of viral transcription will reduce levels of the IFN-antagonists, while also allowing viral replication to proceed, which is a process that can trigger IFN responses. To achieve these goals, the Center, which consists of a diverse team with extensive experience in filovirus biology, antiviral development and medicinal chemistry, will (1) Develop assays and perform HTS screens to identify and optimize small molecule inhibitors of the EBOV and MARV VP35 IFN-antagonists which function to suppress interferon (IFN)-alpha/beta production in filovirus-infected cells. (2) Develop assays and perform HTS screens to identify and optimize small molecule inhibitors of the filovirus antagonists of IFN-induced Jak-STAT signaling, the EBOV VP24 and MARV VP40 proteins. (3) Develop small molecule inhibitors of EBOV and MARV VP30 dephosphorylation that block viral transcription. (4) Evaluate leads and optimized leads for antiviral activity in cell culture and in animal models, prioritizing those with pan-filoviral potential. The expected outcome of this work is the development of inhibitors of filovirus replication that target viral IFN-antagonists and VP30 dephosphorylation and independently display pan-filovirus efficacy in mouse and guinea pig model. We further expect that these therapeutics will exhibit synergistic activities in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109664-01
Application #
8641483
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Program Officer
Beanan, Maureen J
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$3,211,769
Indirect Cost
$387,115
Name
Icahn School of Medicine at Mount Sinai
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ammosova, Tatyana; Platonov, Maxim; Ivanov, Andrei et al. (2014) 1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription. Br J Pharmacol 171:5059-75
Shabman, Reed S; Jabado, Omar J; Mire, Chad E et al. (2014) Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells. MBio 5:e02011
Basler, Christopher F (2014) New hope in the search for Ebola virus treatments. Immunity 41:515-7
Johnson, Joshua C; Martinez, Osvaldo; Honko, Anna N et al. (2014) Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res 107:102-9
Xu, Wei; Edwards, Megan R; Borek, Dominika M et al. (2014) Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16:187-200
Kumari, Namita; Iordanskiy, Sergey; Kovalskyy, Dmytro et al. (2014) Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase I?B-? expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription. Antimicrob Agents Chemother 58:6558-71
Basler, Christopher F; Woo, Patrick C Y (2014) Editorial overview: emerging viruses. Curr Opin Virol 5:v-vii
Ilinykh, Philipp A; Tigabu, Bersabeh; Ivanov, Andrey et al. (2014) Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723-38
Basler, Christopher F (2014) Portrait of a killer: genome of the 2014 EBOV outbreak strain. Cell Host Microbe 16:419-21
Feagins, Alicia R; Basler, Christopher F (2014) The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation. J Virol 88:14440-50